Provided by Tiger Trade Technology Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

79.03
+0.56000.71%
Post-market: 79.030.00000.00%19:57 EDT
Volume:270.11K
Turnover:21.38M
Market Cap:6.17B
PE:79.83
High:79.93
Open:78.28
Low:78.01
Close:78.47
52wk High:82.94
52wk Low:32.89
Shares:78.02M
Float Shares:40.19M
Volume Ratio:0.54
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9900
EPS(LYR):0.7500
ROE:14.04%
ROA:8.05%
PB:9.43
PE(LYR):105.37

Loading ...

Kiniksa launches direct-to-consumer campaign for Arcalyst

TIPRANKS
·
Apr 08

Exploring High Growth Tech Stocks In The US Market March 2026

Simply Wall St.
·
Mar 27

Analysts Offer Insights on Healthcare Companies: CareCloud (CCLD) and Kiniksa Pharmaceuticals (KNSA)

TIPRANKS
·
Mar 14

Kiniksa Pharmaceuticals CMO John F. Paolini Disposes of Common Shares

Reuters
·
Mar 05

How Investors Are Reacting To Kiniksa (KNSA) Turning ARCALYST Revenue Into Full-Year Profitability And Flexibility

Simply Wall St.
·
Mar 05

Is Kiniksa Pharmaceuticals (KNSA) Still Attractive After A 114% One-Year Share Price Surge?

Simply Wall St.
·
Feb 27

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference

Reuters
·
Feb 26

Kiniksa price target raised to $53 from $50 at Wedbush

TIPRANKS
·
Feb 25

Kiniksa Pharmaceuticals Is Maintained at Outperform by Wedbush

Dow Jones
·
Feb 25

Wedbush Adjusts Kiniksa Pharmaceuticals International Price Target to $53 From $50, Maintains Outperform Rating

MT Newswires Live
·
Feb 24

Stock Track | Kiniksa Pharmaceuticals Plummets 9.79% Intraday on Significant Q4 Earnings Miss

Stock Track
·
Feb 24

Kiniksa Pharmaceuticals International plc Publishes Corporate Presentation on ARCALYST Growth and Cardiovascular Pipeline

Reuters
·
Feb 24

Stock Track | Kiniksa Pharmaceuticals Plunges 5.04% in Pre-market on Q4 Earnings Miss

Stock Track
·
Feb 24

Kiniksa reports Q4 EPS 17c, consensus 33c

TIPRANKS
·
Feb 24

Earnings Flash (KNSA) Kiniksa Pharmaceuticals International Posts Q4 EPS $0.17, vs. FactSet Est of $0.34

MT Newswires Live
·
Feb 24

CORRECTED-Kiniksa Pharma Q4 revenue rises on ARCALYST sales

Reuters
·
Feb 24

Kiniksa Pharmaceuticals Q4 EPS $0.17 Misses $0.38 Estimate, Sales $202.127M Beat $195.005M Estimate.

Benzinga Earnings
·
Feb 24

Kiniksa posts FY 2025 ARCALYST net product revenue of USD 677.6 million (62% YoY)

Reuters
·
Feb 24

BRIEF-Kiniksa Pharmaceuticals Q4 EPS USD 0.19

Reuters
·
Feb 24

Kiniksa Pharmaceuticals International Plc: Expects 2026 Arcalyst Net Product Revenue of Between $900 Mln and $920 Mln

THOMSON REUTERS
·
Feb 24